Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 13/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL710791 | 0.80 | MAPK14 (0.65) | CES2 | |
| SCHEMBL710790 | 0.80 | MAPK14 (0.65) | CES2 | |
| SCHEMBL21381217 | 0.80 | VNN1 (0.74) | VNN1 | |
| SCHEMBL20185754 | 0.76 | VNN1 (1.00) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL21557232 | 0.73 | VNN1 (0.43) | VNN1LMNAAURKA | |
| SCHEMBL4848676 | 0.72 | CES2 (0.89) | LMNACES2 | |
| SCHEMBL10051487 | 0.71 | VNN1 (0.47) | VNN1HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL20185841 | 0.71 | VNN1 (1.00) | VNN1LMNACNR2 | |
| SCHEMBL23447718 | 0.71 | LMNA (0.74) | VNN1LMNAHDAC2HDAC6 | |
| SCHEMBL3176325 | 0.71 | CES2 (1.00) | LMNACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242273-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8124765-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-28 | — | — | US | disclosed |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DENG XIAOHU | 2010-10-28 | — | — | US | disclosed |
| US-7807832-B2 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-05 | — | — | US | disclosed |
| WO-2007016286-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027319-A1 | Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine | DCK, DPYD, DTYMK | VNN1 2734/4885LMNA 4732/4885CES2 1662/4885 |
| US-20100274016-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DCK, DPYD, DTYMK | VNN1 2734/4885LMNA 4732/4885CES2 1662/4885 |
| US-20100274015-A1 | SYNTHESIS OF 4/5-PYRIMIDINYLIMIDAZOLES VIA SEQUENTIAL FUNCTIONALIZATION OF 2,4-DICHLOROPYRIMIDINE | DCK, DPYD, DTYMK | VNN1 2734/4885LMNA 4732/4885CES2 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.